2020
Chapter 39 Obsessive–compulsive disorder
Bloch M, Artukoglu B, Lennington J, Szuhay G, Lombroso P. Chapter 39 Obsessive–compulsive disorder. 2020, 663-674. DOI: 10.1016/b978-0-12-813866-3.00039-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsCognitive behavioral therapyTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationBrain stimulantBehavioral therapyMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesFirst-line treatmentSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesNeuroimagingModulating agentsHereditary component
2015
Chapter 106 Obsessive–Compulsive Disorder
Bloch M, Lennington J, Szuhay G, Lombroso P. Chapter 106 Obsessive–Compulsive Disorder. 2015, 1301-1310. DOI: 10.1016/b978-0-12-410529-4.00106-6.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationThalamo-cortical circuitsMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesModulating agentsNeuroimagingHereditary componentCompulsionDeep brainObsession
2011
Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment
Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics 2011, 132: 314-332. PMID: 21963369, PMCID: PMC3205262, DOI: 10.1016/j.pharmthera.2011.09.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment-refractory OCDGlutamate-modulating agentsSmall clinical trialsNew treatment strategiesCompulsive disorderExcitatory neurotransmitter glutamatePathophysiology of OCDGlutamate abnormalitiesGlutamate dysregulationMonoaminergic neurotransmissionCurrent therapiesClinical trialsDopaminergic neurotransmissionTreatment strategiesCognitive-behavioral psychotherapyTherapeutic benefitAnimal modelsNeurotransmitter glutamateNeurochemical investigationsPathophysiologyNew therapeuticsDisordersRecent evidenceMedicationsRecent advances in Tourette syndrome
Bloch M, State M, Pittenger C. Recent advances in Tourette syndrome. Current Opinion In Neurology 2011, 24: 119-125. PMID: 21386676, PMCID: PMC4065550, DOI: 10.1097/wco.0b013e328344648c.Peer-Reviewed Original Research
2005
Clinical treatment of obsessive compulsive disorder.
Pittenger C, Kelmendi B, Bloch M, Krystal JH, Coric V. Clinical treatment of obsessive compulsive disorder. Innov Clin Neurosci 2005, 2: 34-43. PMID: 21120095, PMCID: PMC2993523.Peer-Reviewed Original ResearchObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderMainstay of treatmentSerotonin reuptake inhibitorsEffective treatment modalityUse of clomipramineCurrent treatment strategiesRecent epidemiological studiesCommon psychiatric disordersCompulsive disorderCognitive behavioral therapyInvasive neurosurgical proceduresPartial responseAvailable medicationsPharmacologic treatmentReuptake inhibitorsTreatment armamentariumSignificant morbidityTreatment modalitiesChronic disordersMedication managementTreatment strategiesEpidemiological studiesPsychiatric disordersClinical treatment